Qiagen N.V. (QGEN) : Traders are bullish on Qiagen N.V. (QGEN) as it has outperformed the S&P 500 by a wide margin of 3.6% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.76%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.93% in the last 1 week, and is up 3.04% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.46% and the 50-Day Moving Average is 4.24%.The 200 Day SMA reached 16.91%
Qiagen N.V. (NASDAQ:QGEN): After opening at $26.7, the stock dipped to an intraday low of $26.69 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $27.59 and the buying power remained strong till the end. The stock closed at $27.44 for the day, a gain of 2.81% for the day session. The total traded volume was 1,249,863. The stocks close on the previous trading day was $27.44.
Qiagen N.V. (QGEN) : The most positive equity analysts on Qiagen N.V. (QGEN) expects the shares to touch $30, whereas, the least positive believes that the stock will trade at $24 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $25.81 with an expected fluctuation of $1.93 from the mean.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.